N. J. Raynal

发表

Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer

C. Zahnow, B. Garcia, S. Baylin, 2018, Cell.

Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer

M. Bernstein, R. Momparler, N. J. Raynal, 2008, BMC Cancer.

Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine

M. Bernstein, R. Momparler, N. J. Raynal, 2009, Cancer Chemotherapy and Pharmacology.

3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase.

G. Rivard, R. Momparler, N. J. Raynal, 2011, Leukemia research.

Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation

N. Krogan, A. Haman, T. Hoang, 2019, Journal of Experimental & Clinical Cancer Research.

Optimization of Therapy for Acute Myeloid Leukemia

R. Momparler, N. J. Raynal, 2007 .

Cadmium uptake in isolated adrenocortical cells of rainbow trout and yellow perch.

A. Hontela, N. J. Raynal, C. Jumarie, 2005, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

Antileukemic activity of genistein, a major isoflavone present in soy products.

R. Momparler, M. Charbonneau, N. J. Raynal, 2008, Journal of natural products.

Histone deacetylase inhibitor activity in royal jelly might facilitate caste switching in bees

Jia Li, J. Issa, G. Sbardella, 2011, EMBO reports.

Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells

S. Baylin, J. Issa, R. Najmanovich, 2022, Cancers.

Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells

S. Richard, Zhenbao Yu, J. Masson, 2021, Clinical epigenetics.

Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition

J. Issa, J. Jelinek, M. Estécio, 2013, Genome Biology.

DNA Methyltransferase Inhibitors

J. Issa, N. J. Raynal, 2016 .

Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.

J. Issa, J. Jelinek, H. Kantarjian, 2016, Journal of the National Cancer Institute.

Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome

J. Issa, G. Malouf, Saira S Ahmed, 2016, Molecular Cancer Therapeutics.

DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas

T. Ho, C. Creighton, P. Tamboli, 2016, Clinical Cancer Research.

Efficacy of Combined Epigenetic Therapies

N. J. Raynal, 2016 .

DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory.

J. Issa, J. Jelinek, M. Estecio, 2012, Cancer research.

Epigenetic synergy between decitabine and platinum derivatives

Xin Hu, J. Issa, J. Jelinek, 2015, Clinical Epigenetics.

Targeting MYC Overexpressing Leukemia with Cardiac Glycoside Proscillaridin Through Downregulation of Histone Acetyltransferases

N. Krogan, A. Haman, T. Hoang, 2018, bioRxiv.

DNA Methylation-Targeted Drugs.

N. J. Raynal, Gabrielle McInnes, Annie Beaudry, 2017, Cancer journal.

Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.

S. Baylin, Ying Cui, J. Issa, 2016, Cancer Research.

Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells

R. Najmanovich, D. Sinnett, C. Richer, 2021, Cancer Chemotherapy and Pharmacology.

TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity

J. Pelletier, N. El-Hachem, B. Annabi, 2020, Molecular Cancer Therapeutics.

Synergistic effect of 5-Aza-2'-deoxycytidine and genistein in combination against leukemia.

R. Momparler, M. Charbonneau, N. J. Raynal, 2008, Oncology Research.

Phase I and II studies of the decitabine–genistein drug combination in advanced solid tumors.

I. Plante, L. Yelle, D. Soulières, 2015 .

Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features

V. Paradis, J. Issa, J. Jelinek, 2015, Epigenetics.

Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition

J. Issa, J. Jelinek, Sendurai A Mani, 2013, Genome Biology.

Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and in vivo activity with a water/oil emulsion

C. Richer, X. Banquy, P. St-Onge, 2023, Scientific reports.

Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.

S. Baylin, Ying Cui, J. Issa, 2016, Cancer research.

Abstract 380: Discovery of new epigenetic drugs among FDA-approved drug libraries

S. Baylin, Ying Cui, J. Issa, 2014 .